BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...the years since its founding in 2009, Nimbus Therapeutics LLC...
...2WRN – Werner syndrome RecQ like helicase Danielle Golovin BMS-986165 Nimbus Therapeutics LLC Gilead...
BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...Inc. (NASDAQ:RUBY) hired Jose “Pepe” Carmona as CFO. He held the same title at Radius Health Inc. (NASDAQ:RDUS).Nimbus Therapeutics LLC...
...imaging tech (see “Arch Backs Vizgen’s RNA Imaging Platform”). Jeff Cranmer Merck KGaA Biohaven Pharmaceutical Holding Co. Ltd. Abeona Rubius Therapeutics Nimbus Therapeutics Vizgen BioShin BioShin...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...a member of the board at fellow cancer company CytomX Therapeutics Inc. (NASDAQ:CTMX).Computational chemistry play Nimbus Therapeutics...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...molecules and immuno-oncology, and noted his prior experience with SR One; that firm invested in Nimbus Therapeutics LLC...
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...Kapeller was a GV entrepreneur-in-residence while incubating Rome; she also was computational drug discovery company Nimbus Therapeutics LLC’s...
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...Schrödinger has raised $192.6 million to date, including amounts received from its equity investment in Nimbus Therapeutics LLC...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...an immunomodulatory compound that inhibits HPK1. Burgess believes Treadwell has the most advanced HPK1 inhibitor. Nimbus Therapeutics LLC...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

...internally discovered oncology drug candidates (see “Zentalis Debuts with Three Programs, $85M series C ”). Nimbus Therapeutics LLC...
BioCentury | Oct 30, 2019
Emerging Company Profile

Disc Medicine: Seeking Iron Balance via Hepcidin

...Disc revealed Tuesday a licensing deal with AbbVie Inc. (NYSE:ABBV) and the appointment of former Nimbus Therapeutics LLC...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...was SVP of drug discovery and development at Lysosomal Therapeutics Inc. Computational drug discovery company Nimbus Therapeutics LLC...
...Li, Staff Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4 Pharmaceuticals Inc. Nimbus Therapeutics LLC Canbridge...
Items per page:
1 - 10 of 103
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...the years since its founding in 2009, Nimbus Therapeutics LLC...
...2WRN – Werner syndrome RecQ like helicase Danielle Golovin BMS-986165 Nimbus Therapeutics LLC Gilead...
BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...Inc. (NASDAQ:RUBY) hired Jose “Pepe” Carmona as CFO. He held the same title at Radius Health Inc. (NASDAQ:RDUS).Nimbus Therapeutics LLC...
...imaging tech (see “Arch Backs Vizgen’s RNA Imaging Platform”). Jeff Cranmer Merck KGaA Biohaven Pharmaceutical Holding Co. Ltd. Abeona Rubius Therapeutics Nimbus Therapeutics Vizgen BioShin BioShin...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...a member of the board at fellow cancer company CytomX Therapeutics Inc. (NASDAQ:CTMX).Computational chemistry play Nimbus Therapeutics...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...molecules and immuno-oncology, and noted his prior experience with SR One; that firm invested in Nimbus Therapeutics LLC...
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...Kapeller was a GV entrepreneur-in-residence while incubating Rome; she also was computational drug discovery company Nimbus Therapeutics LLC’s...
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...Schrödinger has raised $192.6 million to date, including amounts received from its equity investment in Nimbus Therapeutics LLC...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...an immunomodulatory compound that inhibits HPK1. Burgess believes Treadwell has the most advanced HPK1 inhibitor. Nimbus Therapeutics LLC...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

...internally discovered oncology drug candidates (see “Zentalis Debuts with Three Programs, $85M series C ”). Nimbus Therapeutics LLC...
BioCentury | Oct 30, 2019
Emerging Company Profile

Disc Medicine: Seeking Iron Balance via Hepcidin

...Disc revealed Tuesday a licensing deal with AbbVie Inc. (NYSE:ABBV) and the appointment of former Nimbus Therapeutics LLC...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...was SVP of drug discovery and development at Lysosomal Therapeutics Inc. Computational drug discovery company Nimbus Therapeutics LLC...
...Li, Staff Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4 Pharmaceuticals Inc. Nimbus Therapeutics LLC Canbridge...
Items per page:
1 - 10 of 103